title: Fludarabine: risk factor for aggressive behaviour of squamous cell carcinoma of the skin?
authors.forename: D
authors.initials: D
authors.lastname: Herr
authors.forename: S
authors.initials: S
authors.lastname: Borelli
authors.forename: W
authors.initials: W
authors.lastname: Kempf
authors.forename: A
authors.initials: A
authors.lastname: Trojan
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced*; D006801:Humans; D016867:Immunocompromised Host; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D012878:Skin Neoplasms / Q000139:chemically induced*; D013601:T-Lymphocytes; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine